2,6-Dimethyloxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2,6-Dimethyloxane-3,4,5-triol
• 化学式: C₇H₁₄O₄
• 分子量: 162.18
• InChiKey: DVZKNXRZLVIBOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  69.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Heterobifunctional pan-selectin inhibitors
  申请人：Magnani L. John

  公开号：US20070054870A1

  公开（公告）日：2007-03-08

  Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).

  提供了用于调节体外和体内由选择素结合介导的过程的化合物和方法。更具体地描述了选择素调节剂及其用途，其中调节选择素介导功能的选择素调节剂包括特定的糖类似物，单独或与一类被称为BASAs（苯甲基氨基磺酸）的化合物或一类被称为BACAs（苯甲基氨基羧酸）的化合物中的成员相连。
• [EN] HETEROBIFUNCTIONAL PAN-SELECTIN ANTAGONISTS HAVING A TRIAZOLE LINKER<br/>[FR] ANTAGONISTES HÉTÉROBIFONCTIONNELS DE PAN-SÉLECTINE PRÉSENTANT UN LIEUR DE TYPE TRIAZOLE
  申请人：GLYCOMIMETICS INC

  公开号：WO2017095904A1

  公开（公告）日：2017-06-08

  Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids). The compounds are of formula (la) wherein the substituents are as defined in the claims.

  用于调节体外和体内由选择素结合介导的过程的化合物、组合物和方法。例如，描述了抑制E-选择素和P-选择素的异双功能化合物，其中调节选择素的调节剂（例如，抑制或增强）选择素介导功能的包括特定的糖类似物与一类被称为BASAs（苄基氨基磺酸）的化合物结合的成员。这些化合物的化学式为（la），其中取代基如权利要求中所定义。
• Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
  申请人：Houlmont Jean-Philippe

  公开号：US20070134187A1

  公开（公告）日：2007-06-14

  The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C 2 -C 40 , said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C 2 -C 40 .

  该发明涉及一种药物，包括至少一种含有羟基功能的还原烷基糖单体，该羟基功能在C2-C40处被烷氧基取代，所述药物通常用于调节炎症机制。还原糖通常选自包含鼠李糖、岩藻糖和葡萄糖的组。该发明还涉及一种化妆品处理方法，涉及局部应用包含至少一种含有羟基功能的还原烷基糖单体，该羟基功能在C2-C40处被烷氧基取代的组合物。
• SENESCENCE TRACERS
  申请人：Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet

  公开号：US20150168374A1

  公开（公告）日：2015-06-18

  The instant invention relates to novel compounds useful for visualizing cell senescence, their preparation and use. In particular, this invention relates to novel fucose and aminoquinoline derivatives useful as senescence traces and their preparation.

  这项即时发明涉及用于可视化细胞衰老的新化合物，它们的制备和使用。具体来说，这项发明涉及用作衰老迹象的新葡萄糖和氨基喹啉衍生物以及它们的制备。
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES
  申请人：Young Andrew A.

  公开号：US20120157399A1

  公开（公告）日：2012-06-21

  Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

  本文提供了利用胆汁酸转运抑制剂治疗肥胖症和糖尿病的方法。